Cargando…

Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma

Ameloblastoma is the most common benign odontogenic neoplasm, but with an aggressive behavior and a high recurrence rate. Nowadays wide surgical resection is the current recommended treatment, which can cause further loss of function and esthetics. Recent studies point to the stem/progenitor cells a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tseng, Chih-Huang, Lu, Pei-Hsuan, Wang, Yi-Ping, Chang, Julia Yu Fong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780877/ https://www.ncbi.nlm.nih.gov/pubmed/35055392 http://dx.doi.org/10.3390/jpm12010077

Ejemplares similares

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

High frequency of BRAF V600E mutation in Iranian population ameloblastomas
por: Derakhshan, Samira, et al.
Publicado: (2020)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2022)

Machine learning-based radiomics for predicting BRAF-V600E mutations in ameloblastoma
por: Li, Wen, et al.
Publicado: (2023)

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
por: Fernandes, Gustavo S., et al.
Publicado: (2018)

Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study
por: Shirsat, Pankaj M, et al.
Publicado: (2018)

Recurrent ameloblastoma with both hypercalcemia and BRAF mutation: A case report
por: Suzuki, Hidenori, et al.
Publicado: (2020)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
por: Burger, Michael C., et al.
Publicado: (2017)

Association of microRNA Expression and BRAF(V600E) Mutation with Recurrence of Thyroid Cancer
por: Pamedytyte, Daina, et al.
Publicado: (2020)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
por: Park, Charny, et al.
Publicado: (2015)

Adult classical glioblastoma with a BRAF V600E mutation
por: Takahashi, Yoshinobu, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

Thymic Adenocarcinoma with Positivity for Thyroid Transcription Factor-1 and a BRAF V600E Mutation
por: Yorozuya, Takafumi, et al.
Publicado: (2021)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie, Florin, et al.
Publicado: (2015)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

Somatic V600E BRAF mutation in linear and sporadic syringocystadenoma papilliferum
por: Levinsohn, Jonathan L., et al.
Publicado: (2015)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
por: Gow, Chien-Hung, et al.
Publicado: (2019)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

The Sensitivity and Specificity of Novel Primers for Detection of BRAF(V600E) Mutation
por: Tayeb, Bizhar A, et al.
Publicado: (2020)

Treatment of BRAF V600E mutated ganglioglioma of the third ventricle with dabrafenib
por: Kilmister, Ethan John, et al.
Publicado: (2021)

Insight on BRAF(V600E) mutated colorectal cancer immune microenvironment
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry
por: Swan, Kristine Zøylner, et al.
Publicado: (2022)

BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
por: Bui Dang Minh, Tri, et al.
Publicado: (2023)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ug2ervngst6u39aqc7fkscva9g